Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer

Faculty

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Identification of Appropriate Candidates with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) for Agents Targeting the PI3K/AKT/mTOR Pathway

• Incidence of relevant biomarkers, including alterations along the PI3K/AKT/mTOR pathway, in HR-positive, HER2-negative mBC
• Clinical characteristics associated with PI3K/AKT/mTOR pathway alterations in HR-positive, HER2-negative mBC
• Optimal methodology for and timing of assessment for alterations along the PI3K/AKT/mTOR pathway for HR-positive, HER2-negative mBC
• Role of oncology nurses in facilitating biomarker testing for HR-positive, HER2-negative mBC and helping patients understand the implications of the results

MODULE 2: Role of Inavolisib in the Management of HR-Positive mBC

• Mechanistic similarities and differences between inavolisib and earlier-generation PI3K inhibitors (ie, alpelisib); implications for efficacy and tolerability
• Key findings with inavolisib in combination with palbociclib and fulvestrant as first-line therapy for patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative mBC
• FDA approval of inavolisib/palbociclib/fulvestrant, and current clinical role for newly diagnosed HR-positive, HER2-negative mBC with a PIK3CA mutation
• Ongoing evaluation of inavolisib for endocrine-sensitive, PIK3CA-mutated, HR-positive, HER2-negative mBC; potential role in this setting

MODULE 3: Adverse Events (AEs) Associated with Inavolisib

• Incidence of hyperglycemia with inavolisib; optimal monitoring of fasting glucose levels and HbA1c
• Appropriate management of hyperglycemia occurring with inavolisib; indications for antidiabetic medications and dose modifications
• Incidence of gastrointestinal (GI) toxicities (eg, diarrhea, stomatitis, nausea) with inavolisib; strategies for mitigation and management
• Spectrum, frequency, severity and management of other toxicities (eg, cytopenias, fatigue, rash) documented with inavolisib-containing therapy

MODULE 4: Clinical Utility of Capivasertib in the Management of HR-Positive mBC

• Biological rationale for inhibiting AKT in the management of HR-positive mBC; mechanism of action of capivasertib
• Key efficacy and safety data with capivasertib/fulvestrant for recurrent HR-positive, HER2-negative mBC
• FDA approval of capivasertib for patients with HR-positive, HER2-negative mBC with PIK3CA/AKT1/PTEN alterations, and current role opposite other evidence-based options
• Ongoing evaluation of the triplet combination of capivasertib, fulvestrant and a CDK4/6 inhibitor as first-line therapy for patients with HR-positive, HER2-negative mBC who experience disease progression on or within 12 months of completing (neo)adjuvant endocrine therapy

MODULE 5: Side Effects and Other Practical Considerations with Capivasertib

• Recommended management strategies for patients experiencing diarrhea and other GI disorders while receiving capivasertib
• Pathophysiology, spectrum and optimal treatment of cutaneous adverse reactions with capivasertib
• Incidence of hyperglycemia in patients receiving capivasertib; indications for blood glucose monitoring and role, if any, for patients with preexisting diabetes
• Dose, schedule and recommended approach to dose modifications with capivasertib

MODULE 6: Potential Role of Gedatolisib in the Management of HR-Positive mBC

• Mechanistic similarities and differences between gedatolisib and currently approved therapies targeting the PI3K/AKT/mTOR pathway for HR-positive mBC; implications for antitumor activity
• Recently presented data from the PIK3CA wild-type cohort of a Phase III study evaluating gedatolisib in combination with fulvestrant with or without palbociclib for patients with HR-positive, HER2-negative mBC whose disease progressed on or after prior CDK4/6 inhibitor therapy and an aromatase inhibitor
• Anticipated read-out of the PIK3CA-mutated cohort of the aforementioned study
• Potential role of gedatolisib-containing combination therapy for pretreated HR-positive, HER2-negative mBC that is PIK3CA wild type and PIK3CA mutated

MODULE 7: Tolerability Profile of Gedatolisib

• Rates of treatment discontinuation due to an AE documented with gedatolisib/palbociclib/fulvestrant and gedatolisib/fulvestrant
• Incidence and severity of hyperglycemia and diarrhea with gedatolisib-based therapy relative to other agents targeting the PI3K/AKT/mTOR pathway
• Spectrum and incidence of other treatment-related AEs documented with gedatolisib-based therapy (eg, stomatitis, neutropenia, nausea, vomiting, rash, fatigue)
• Strategies to monitor for, mitigate and manage treatment-related AEs with gedatolisib

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Review available research documenting the correlation between various biomarkers, such as PIK3CA/AKT1/PTEN alterations and ESR1 mutations, and response to specific therapies, and understand optimal testing algorithms for patients with hormone receptor (HR)-positive metastatic breast cancer (mBC).
• Recognize the frequency of PIK3CA/AKT/PTEN alterations in HR-positive mBC, and educate patients with newly diagnosed and relapsed/refractory disease about evidence-based approaches to targeting these aberrations.
• Understand the biological rationale for the development of agents targeting multiple components of the PI3K/AKT/mTOR pathway, and recognize available and emerging data with this strategy for patients with HR-positive, PIK3CA wild-type and PIK3CA-mutant mBC.
• Assess the spectrum, frequency and severity of adverse events associated with available and emerging agents targeting the PI3K/AKT/mTOR pathway, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Evaluate available research findings with and ongoing studies evaluating novel PI3K/AKT/mTOR inhibitor-based approaches, and consider the potential role of these strategies.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/PI3KAKTmTORMetastaticBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Basho — Advisory Committees: AstraZeneca Pharmaceuticals LP, Celcuity, Novartis, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Scorpion Therapeutics; Data and Safety Monitoring Boards/Committees: Pfizer Inc; Speakers Bureaus: DAVA Oncology, MDOutlook; Nonrelevant Financial Relationships: Community Health Media, OncLive, Targeted Oncology. Ms Rikal — Advisory Committees: Stemline Therapeutics Inc; Consulting Agreements and Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. Additional faculty to be announced.

MODERATOR — Dr Wander — Consulting Agreements: Arvinas, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Biovica International AB, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics, Stemline Therapeutics Inc, Veracyte Inc; Contracted Research: Arvinas, Genentech, a member of the Roche Group, Lilly, Menarini Group, Nuvation Bio Inc, Pfizer Inc, Phoenix Molecular Designs, Puma Biotechnology Inc, Regor Therapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celcuity, and Genentech, a member of the Roche Group.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.